Crescent Biopharma (CBIO) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.86

Estimate

-$0.57

Surprise

-50.5%

Revenue (period 2026-09-30)

$3.1M

Score today

5.3/10

Revenue source: xbrl.

Crescent Biopharma (CBIO) reported a wider loss than forecast — adjusted EPS of -$0.86 against the -$0.57 estimate (a 50.5% shortfall).

• HC Wainwright & Co. Raises Crescent Biopharma Price Target to $40 — fiscal.ai, 2026-11-14
• Wedbush Adjusts Price Target on Crescent Biopharma to $31 — fiscal.ai, 2026-11-13
• Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32 — benzinga, 2026-11-13

TrendMatrix currently rates CBIO Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -50.5% surprise compares with a -24.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$14.15

Price target

$28.13

Stop

$13.16

Upside to target

+98.8%

Reward-to-risk

6.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$591.3M

P/E (fwd)

-5.4

52-week range

$8.72–$27.41

Off 52-week high

48.4%

RSI (14)

60

Volume vs avg

1.24×

Score today

5.3/10